Cellular Health Screening Market Size, Share & Trends Analysis Report By Test Type (Single Test Panels, Multi-test Panels), By Sample Type (Blood, Urine), By Collection Site, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Cellular Health Screening market size was estimated at USD 3.5 billion in 2022 and is projected to hit around USD 6.2 billion by 2030, growing at a CAGR of 9.20% during the forecast period 2022 to 2030.

Key Takeaways:

• By test type, single test panels held the largest share in 2022. This is attributed to high specificity, easy customization, and increasing product availability in the market
• In the single test panels segment, the oxidative stress tests captured the largest share in 2022. These tests aid in cancer, respiratory diseases, diabetes, cardiovascular diseases, and other diseases
• Based on sample type, the blood sample segment accounted for the largest share in 2022. The growing incidence of infectious diseases, emergence of newer pathogens, increasing demand for donated blood, and rising number of blood donations have contributed to the rising demand for blood samples for cellular health screening
• By collection site, hospitals captured the largest revenue share in 2022. A major part of the general population relies on these long-term facilities for diagnosis, treatment, and management of diseases, thus driving the segment
• North America accounted for the largest market share in 2022. An increase in the importance of Healthy Life Expectancy (HALE) and increasing number of government initiatives focused on preventive healthcare are some of the key factors expected to boost the market growth in the region
• Asia Pacific is expected to witness the fastest growth throughout the forecast period. Improving adoption and awareness of telomere performance programs and growing awareness of healthy life expectancy have contributed to regional growth

The growing geriatric population and consequent growth in the requirement for cellular health screening are majorly driving the market. In addition, the rising adoption of the direct-to-consumer approach, the growing importance of healthy life expectancy (HALE), increasing telomere performance programs for leading a healthy life, and rising government focus on preventive healthcare are expected to drive the market.

An increasing number of individuals undergoing cellular health screening testing, such as telomere tests, to learn about the biomarkers of cell aging is also anticipated to supplement the market growth. It has been demonstrated that tests that provide information on telomere length and activity can also provide information on lifestyle and stress factors. Numerous studies have demonstrated that both acute stress and chronic stress accelerate cell aging. Thus, these tests play an important role in understanding one’s health.

Additionally, researchers can gain insights into cellular qualities by studying how physical exercise, sleep, mental health issues, alcohol use, and smoking habits alter cellular aging in various ways. The utilization of telomere tests offers insights into metabolic and genetic illnesses, enabling clinicians to make an early diagnosis and quickly and individually tailor a patient's treatment regimen. Consequently, growing interest in cellular screening and expanding research have increased kit and test demand, facilitating market growth in recent years.

The necessity for cellular screening research has grown as a result of its many applications in preventive medicine and the capacity to comprehend relationships between telomere length and aging. Bio-cell-based screenings are frequently advised throughout time, allowing patients to compare results and comprehend what modifications need to be made. Monitoring these alterations in cellular health between screenings enables quick adjustments to be made in terms of health protocols and a general improvement in illness management.

Furthermore, disorders related to aging are linked to the buildup of old, dysfunctional cells. As shown in several animal trials, research has recently established that these can be reversed by employing a variety of cellular health procedures. Consequently, it is anticipated that ongoing research and development activities in the disciplines of protein expression, proteomics, and genomics are anticipated to further boost the demand for cellular health screening products in the near future.

Report Scope of the Cellular Health Screening Market

Report Coverage	Details
Market Size	USD 6.2 Billion by 2030
Growth Rate	CAGR of 9.20% from 2022 to 2030
Largest Market	Asia Pacific
Fastest Growing Market	North America
Base Year	2022
Forecast Period	2022 to 2030
Segments Covered	and Region,
Companies Mentioned	Telomere Diagnostics; SpectraCell Laboratories; Life Length; Repeat Diagnostics, Inc.; Cell Science Systems Corp.; Quest Diagnostics; LabCorp Holdings; OPKO; Genova Diagnostics; Immundiagnostik AG; DNA Labs

 

Test Type Insights

The single test panels segment held the largest share of over 76.0% in 2022. Among the cellular health screening tests for telomere, inflammation, oxidative stress, and heavy metals, the telomere single test panel is expected to grow at the fastest rate over the forecast period. This can be attributed to various research studies showing the correlation of telomere length on multiple molecular and cellular functions. Moreover, the launch of new testing devices for the detection of telomere length further contributes to the growth. For instance, in September 2022, Genomic Vision launched TeloSizer to boost the use of telomere for biomarker discovery via its precise and quantitative detection.

The multi-test panels segment is estimated to witness the fastest growth during the forecast period. The utilization of these panels for screening multiple biomarkers during a single run has resulted in many advantages such as diagnostic competence, precision, and reduced costs in health care settings. These reasons are anticipated to increase the inclination toward multi-test panels rather than single-use panels in the future.

Sample Type Insights

Blood sample dominated the market with a share of over 46.0% in 2022. The frequent use of blood samples by clinicians and the application of diagnostic kits for evaluating various disease conditions, organ functioning, and risk factor analysis are the factors supporting the growth of the segment. Additionally, the launch of new diagnostic devices that use blood for detection and screening is boosting market growth. For instance, a blood-testing startup, Osler is tapping investors for funds before the big launch of its diagnostic device. The new technology will deliver results in 10 minutes and it aims at providing cheap blood tests.

Urine sample will observe significant growth in the forecast period. Urine collection is patient-friendly as it is non-invasive and much quicker because it doesn’t require technical personnel. Research has also demonstrated that oxidative stress can be successfully evaluated from urine screening. For instance, in a research article published in July 2020, researchers from Japan proved that the presence of pteridine derivatives in urine is associated with oxidative stress and smoking. Thus, the increased testing of oxidative stress in the human body is also expected to fuel the growth of urine sample type screening in the market.

Collection Site Insights

In 2022, the hospital segment accounted for the largest revenue share of over 36.0%. For the majority of the population, hospitals are the center for primary diagnosis and treatment. The use of diagnostic kits for both in-patients and out-bound patients for health screening is one of the major factors contributing to the growth. Moreover, the presence of medical professionals and the recommendation of diagnostic tests for disease identification are fueling the growth of the market. The presence of sample collection sites, skilled professionals, and advanced diagnostic techniques in one place is anticipated to further contribute to the growth.

The home segment is estimated to grow at the fastest rate throughout the forecast period. This can be attributed to the increasing awareness regarding health and self-sampling adoption in major markets. The adoption of self-sampling is because it is user-friendly and doesn’t require specific infrastructure or trained professionals. Moreover, the COVID-19 pandemic led to the mass preference for home collections due to limited movements and this preference will continue even in the years to come. For example, Lab Corp announced in April 2022 that it has launched a home collection service for various diagnostic and screening test offerings of the company.

Regional Insights

North America accounted for a dominant share of over 46.2% in 2022. The rising awareness regarding health among individuals driving the Healthy Life Expectancy (HALE), growing healthcare expenditure, and government funding for preventative healthcare are some of the key contributing factors in this region. Furthermore, the presence of major key players, easy adoption of new technologies, and the burden of infectious and chronic diseases in the population are contributing to regional growth.

Asia Pacific is expected to emerge as the fastest-growing regional market over the forecast period. This is owing to the presence of a growing population that contributes to a larger patient pool and the developing healthcare infrastructure due to increasing economies. The improved adoption of tests and health consciousness among adult individuals are the key driving factors in the Asia Pacific. Moreover, the increased research on telomere for senescence and government initiatives for the prevention of diseases is supporting regional growth.

Some of the prominent players in the Cellular Health Screening Market include:

• Telomere Diagnostics
• SpectraCell Laboratories
• Life Length
• Repeat Diagnostics, Inc.
• Cell Science Systems Corp.
• Quest Diagnostics
• LabCorp Holdings
• OPKO
• Genova Diagnostics
• Immundiagnostik AG
• DNA Labs 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cellular Health Screening market

• Test Type
• Single Test Panels

• Telomere Tests
• Oxidative Stress Tests
• Inflammation Tests
• Heavy Metals Tests
• Multi-test Panels
• Sample Type
• Blood
• Saliva
• Serum
• Urine
• Collection Site
• Home
• Office
• Hospital
• Diagnostic Labs

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Cellular Health Screening industry analysis from 2022 to 2030 to identify the prevailing Cellular Health Screening industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Cellular Health Screening industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Cellular Health Screening industry trends, key players, market segments, application areas, and market growth strategies.